1 week ago
Polaryx Therapeutics Inc. (NASDAQ:PLYX) stock tumbled Wednesday, giving back gains after a sharp one-day surge sparked by a major clinical development announcement on Tuesday.
The stock closed Tuesday up 64.32% at $3.96, after the company announced it had selected a contract research organization (CRO) for its SOTERIA Phase 2 basket trial.
The trial is designed to evaluate PLX-200, Polaryx’s lead candidate, across multiple lysosomal storage disorders.
Polaryx said the CRO selection marks a pivotal milestone as it prepares to initiate the trial in the first half of ...
